|
本帖最后由 LadySecilia 于 15-7-10 14:31 编辑
Lamotrigine in the immediate treatment of outpatients with depersonalization disorder without psychiatric comorbidity: randomized, double-blind, placebo-controlled study.
Abstract
OBJECTIVE:
Depersonalization disorders (DPDs) are highly prevalent in population. However, the effect of lamotrigine on outpatients with DPD without psychiatric comorbidity has not been studied in a double-blind placebo-controlled design.
METHOD:
Eighty patients (all men) were washed out from all medications. Each patient was randomized either to receive lamotrigine (40 patients) for 12 weeks or matched on placebo (40 patients) in a double-blind manner. Eligible participants, in addition to meeting the criteria for DPD from Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision, were required to be between 18 and 65 years. Response was defined as a 50% reduction in the Cambridge Depersonalization Scale. Response effects with lamotrigine and placebo were compared by using analysis of variance and χ2 tests. Six patients did not return for at least 1 subsequent assessment, and 74 patients dropped out (36 taking lamotrigine and 38 taking placebo) in the valuables study group.
RESULTS:
Of the 36 lamotrigine-treated participants, 26 responded by 12 weeks versus 6 of the 38 placebo-treated participants (P < 0.001). The most common and problematic adverse effect in the lamotrigine group was rash.
CONCLUSIONS:
The authors believe this to be the first double-blind placebo-controlled randomization study to test the efficacy of lamotrigine in the management of outpatients with DPDs. These need to be replicated in a larger study group.
标题:论拉莫三嗪对人格解体患者(没有其他精神疾病的门诊病人)即刻治疗的疗效:一项随机、双盲、有安慰剂对照的研究。
研究目的:人格解体障碍是常见的。但是关于拉莫三嗪对人格解体患者(没有其他精神疾病的门诊病人)的疗效,此前还没有研究者做过有安慰剂对照的双盲实验。
研究方法:令80名病人(男性,18-65岁)停止所有原来的药物治疗后,随机分配到拉莫三嗪组(40人)和安慰剂组(40人),进行为期12周的双盲实验。全部受试者都符合xxx量表(量表名字我就不翻了,太麻烦)对于人格解体障碍的诊断标准。以剑桥人格解体量表数值下降百分之50作为有治疗反应的标准。
12周中,有6名受试者没有坚持至少1次以上的后续评估。74名受试者(拉莫三嗪组36人,安慰剂租38人)从valuables study group (直译出来是贵重物品研究小组,我也不知道这是什么鬼)中退出。
实验结果:截至实验结束,36名拉莫三嗪组受试者中有26名有治疗反应;38名安慰剂组受试者中有6人有治疗反应。拉莫三嗪组中最普遍和令受试者反感的副作用是皮疹。
研究结论:为了更准确地确定拉莫三嗪在人格解体治疗方面的效果,还需要扩大样本数量进行进一步的研究。
________________________________
概括一下就是,在这个实验里,拉莫三嗪对人格解体症状有改善。但是样本太小了,所以并没有什么说服力。而且,这个实验的受试者全都是没有合并其他精神病症状的单纯的人格解体患者。
|
|